Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Nektar Therapeutics (NASDAQ: NKTR) closed the day trading at $0.85 down -9.35% from the previous closing price of $0.93. In other words, the price has decreased by -$9.35 from its previous closing price. On the day, 2.31 million shares were traded.
Ratios:
For a better understanding of NKTR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on January 08, 2025, initiated with a Buy rating and assigned the stock a target price of $4.
On December 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.50.
On November 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 04, 2024, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 19 ’25 when Zalevsky Jonathan sold 10,300 shares for $1.01 per share. The transaction valued at 10,403 led to the insider holds 316,604 shares of the business.
Wilson Mark Andrew sold 11,040 shares of NKTR for $11,150 on Feb 19 ’25. The Chief Legal Officer now owns 324,292 shares after completing the transaction at $1.01 per share. On Feb 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,774 shares for $1.01 each. As a result, the insider received 24,012 and left with 1,086,901 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.67 while its Price-to-Book (P/B) ratio in mrq is 3.19.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.63. The 50-Day Moving Average of the stock is -7.97%, while the 200-Day Moving Average is calculated to be -29.78%.
Shares Statistics:
A total of 184.46M shares are outstanding, with a floating share count of 177.74M. Insiders hold about 3.64% of the company’s shares, while institutions hold 70.10% stake in the company.
Earnings Estimates
Nektar Therapeutics (NKTR) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.2 and low estimates of -$0.22.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is -$0.86, with 2 analysts recommending between -$0.82 and -$0.9.
Revenue Estimates
9 analysts predict $36.65M in revenue for the current quarter. It ranges from a high estimate of $91M to a low estimate of $17.58M. As of the current estimate, Nektar Therapeutics’s year-ago sales were $23.89MFor the next quarter, 9 analysts are estimating revenue of $22.39M. There is a high estimate of $30.7M for the next quarter, whereas the lowest estimate is $15.74M.
A total of 9 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $160.25M, while the lowest revenue estimate was $86.83M, resulting in an average revenue estimate of $105.92M. In the same quarter a year ago, actual revenue was $90.12MBased on 9 analysts’ estimates, the company’s revenue will be $79.66M in the next fiscal year. The high estimate is $130.12M and the low estimate is $35M.
